A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: The CLO-CLO trial by Oberhänsli, Markus et al.
A  randomized  comparison  of platelet  reactivity  in
patients after  treatment  with  various  commercial
clopidogrel preparations:  The  CLO-CLO  trial
Étude  randomisée  comparant  la  réactivité  plaquettaire  des  patients  traités  par
diverses  préparations  commerciales  de  clopidogrel.  Étude  CLO-CLO
Markus  Oberhänsli, Cédric  Lehner,
Serban  Puricel, Sonja  Lehmann, Mario  Togni,
Jean-Christophe  Stauffer, Gérard  Baeriswyl,
Jean-Jacques  Goy ∗,  Stéphane  Cook
Service  de  Cardiologie,  Hôpital  Cantonal,  1700  Fribourg,  Switzerland
KEYWORDS
Antiplatelet;
Aspirin;
Clopidogrel;
Percutaneous
coronary  intervention
Summary
Background.  —  The  salt  linked  to  the  clopidogrel  molecule  in generic  preparations  is  suspected
to  affect  its  clinical  efﬁcacy.  There  is  a  lack  of  information  about  inhibition  of  platelet  reactivity
by  generic  preparations.
Aims. —  To  compare  the  effect  of original  clopidogrel  (clopidogrel  bisulphate  [Plavix®]),  generic
clopidogrel  preparations  (clopidogrel  hydrochloride  [Clopidogrel-Mepha®];  clopidogrel  besylate
[Clopidogrel  Sandoz®])  and  prasugrel  (Eﬁent®) on  platelet  reactivity  in  patients  with  coronary
artery  disease.
Methods.  —  Patients  with  coronary  artery  disease  treated  with  stents  received,  in a random
sequence,  original  clopidogrel  bisulphate,  clopidogrel  hydrochloride  and  clopidogrel  besylate.
Platelet  function  was assessed  with  the  Multiplate  analyser  after  an initial  loading  dose  (600  mg)
and  at  day  10  after  each  treatment  period.  Prasugrel  was given  for another  10  days.  An  adenosine
diphosphate  (ADP)  test  value  <  46  antiaggregation  units  (U) was deﬁned  as  therapeutic  platelet
inhibition.
Results.  —  Sixty  patients  (mean  age  69 ±  10  years;  50 men)  were  randomized.  Original  clopido-
grel  bisulphate,  clopidogrel  hydrochloride  and  clopidogrel  besylate  provided  similar  inhibition
Abbreviations: ADP,  adenosine diphosphate; PCI,  percutaneous coronary intervention; U, antiaggregation units.
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of  platelet  reactivity  with  values  of 31 ±  25,  33  ±  28  and  28  ±  23  U,  respectively  (P  not  sig-
niﬁcant).  Prasugrel  provided  better  inhibition  of  platelet  function  (10  ±  11 vs.  31  ±  25  U  for
clopidogrel  bisulphate;  P <  0.001).  An  ADP  test  value  > 46 U was measured  in 11  patients  (18%)
with  clopidogrel  bisulphate,  13  (22%)  with  clopidogrel  besylate  and  13  (22%)  with  clopidogrel
hydrochloride  compared  with  only  one  (2%)  with  prasugrel.  Conclusion  Generic  clopidogrel
preparations  provided  similar  inhibition  of  platelet  reactivity  to  original  clopidogrel  bisulphate,
although  prasugrel  was more  efﬁcient.
©  2012  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Objectifs.  —  Le but  de  cette  étude  est  de  comparer  l’effet  sur  l’agrégation  plaquettaire  de  la
molécule originale  de  clopidogrel  (clopidogrel  bisulfate  [Plavix®])  aux  molécules  génériques
(clopidogrel  besylate  [clopidogrel  Sandoz®] et  clopidogrel  hydrochloride  [clopidogrel-Mepha®])
et au prasugrel  (Eﬁent®).
Historique.  —  On  suspecte  que  le  sel  utilisé  pour  lier  la  molécule  de  clopidogrel  pourrait  changer
l’efﬁcacité  du  médicament  et par  là  même avoir  un impact  sur  son  activité  d’antiagrégant
plaquettaires. Aucune  information  n’est  actuellement  disponible.
Méthode.  —  Des  patients  avec  maladie  coronaire  traités  par  angioplastie  et  mise  en  place  de
stent ont  été  inclus  dans  cette  étude.  Ils  ont  rec¸u  de  manière  randomisée  les  trois  molécules  de
clopidogrel,  à  savoir  le clopidogrel  bisulfate  (Plavix®),  le  clopidogrel  hydrochloride  (Clopidogrel-
Mepha®)  et  le  clopidogrel  besylate  (Clopidogrel  Sandoz®)  pour  une  durée  de  dix  jours  chacune.
Après  cette  période  de  30  jours  les  malades  étaient  placés  sous  prasugrel  pour  une  nouvelle
période  de  dix jours.  L’agrégation  plaquettaire  a  été  mesurée  après  la  dose  de  charge  (600  mg)
et  après  chaque  intervalle  de  traitement  de  dix  jours.  Un  appareil  de  type  Multiplate  Analyzer  a
été  utilisé  pour  évaluer  la  fonction  plaquettaire.  Une valeur  d’ADP  inférieure  à  46  U représentait
une  antiagrégation  plaquettaire  efﬁcace.
Résultats.  —  Soixante  patients  (50  hommes)  avec  un âge  moyen  de  69  ±  10  ans  ont été  inclus.  Il
n’y  avait  pas  de  différence  signiﬁcative  de  l’activité  antiagrégante  entre  les  trois  préparations
de  clopidogrel,  le  clopidogrel  bisulfate,  le  clopidogrel  hydrochloride  et le  clopidogrel  besylate
avec  des  valeurs  d’ADP  de, respectivement,  31 ±  25 U,  33 ±  28  et 28  ±  23 U (p = NS).  Le  prasugrel
est  signiﬁcativement  plus  efﬁcace  que  l’ensemble  des  clopidogrel  ;  10  ±  11 U vs.  31  ±  25  U.  Une
valeur  d’ADP  supérieure  à  46  U a  été  observée  chez  11 malades  avec  le clopidogrel  bisulfate
(19,6  %), 12  malades  (21,1  %)  avec  le  clopidogrel  besylate  et  13  malades  (23,2  %)  avec  le clopid-
ogrel  hydrochloride.  Seul  un  patient  (2,3  %)  avec  le  prasugrel  avait  une valeur  d’ADP  supérieure
à  46 U.
Conclusion.  — Le niveau  d’antiagrégation  plaquettaire  obtenu  avec  les  préparations  génériques
de clopidogrel  est  comparable  à celui  obtenu  avec  la  forme  originale  alors  que  le  prasugrel  est
plus  efﬁcace.
© 2012  Elsevier  Masson  SAS.  Tous  droits  réservés.
Background
Dual  antiplatelet  therapy  with  aspirin  and  thienopyridine  is
essential after  coronary  intervention  and  stent  placement
[1—3]. The  level  of  on-treatment  platelet  reactivity  is asso-
ciated with  long-term  adverse  cardiovascular  events  after
percutaneous coronary  intervention  (PCI)  [4].  The  efﬁcacy
of such  treatment  is  largely  inﬂuenced  by  interindividual
variability in  the pharmacodynamic  response  to  clopidogrel
[5,6]. In  addition,  clopidogrel  recently  became  generic;  sev-
eral commercial  preparations  are  now  available  in which
clopidogrel is linked  to  a salt  that  might  change  its  clini-
cal efﬁcacy.  None  of these  generic  preparations  has  been
validated other  then  by  pharmacodynamic  tests.  In this
prospective trial,  we use  a  platelet  function  test  [7]  to  com-
pare, in  routine  clinical  practice,  platelet  reactivity  after
randomized administration  of two  new  generic  clopidogrel
preparations (clopidogrel  besylate  [Clopidogrel  Sandoz®]
and  clopidogrel  hydrochloride  [Clopidogrel-Mepha®])  and
the original  preparation  (clopidogrel  bisulphate  [Plavix®]).
Methods
Patient selection  and  study design
Consecutive  patients  with  ischaemic  heart  disease  under-
going PCI  with  stent  implantation  were considered  for
enrolment in this  trial.  PCI  was performed  using  standard
techniques by  the  femoral  or  radial  route.  Exclusion  crite-
ria were:  cardiogenic  shock;  pregnancy;  intolerance  to
aspirin, thienopyridine  or  contrast  media;  poor  compli-
ance; active  bleeding;  inability  to  give  informed  consent;
anaemia; thrombocytopenia;  moderate-to-severe  renal  fail-
ure  (deﬁned  as  creatinine  clearance  of 30  to  60  mL/min
and < 30  mL/min,  respectively);  planned  surgery;  or  inabil-
ity to  have  follow-up  information.  Patients  already  treated
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Figure 1. Trial design. ADP:  adenosine diphosphate; PCI:  percutaneous coronary intervention.
with  thienopyridines  were  equally  excluded.  All patients
gave their  written  informed  consent  and  the  protocol  was
approved by  the  hospital’s  ethical  committee.  The con-
trol group  was  composed  of 50  healthy  medication-free
adults. The  subjects  in  the control  group  did  not  receive  any
antiplatelet therapy.  The  rationale  behind  having  a control
group was  to  conﬁrm  the validity  of  the  platelet  aggregation
test.
This was  a  single-blind  randomized  trial  with  complete
crossover (Fig.  1). The  primary  endpoint  was  therapeutic
antiaggregation deﬁned  as  a value  of  <  46  antiaggregation
units (U)  on  whole  blood  platelet  function  testing.  Random-
ization was  achieved  with  envelopes,  the  patients  being
assigned to  one  of  the  three  clopidogrel  groups  for 10  days,
then crossed  over  to  another  clopidogrel  molecule,  as  shown
in Fig.  1.
Percutaneous coronary intervention and
antiplatelet  therapy  management
At  the  time  of  PCI, all  patients  received  500  mg  of aspirin  in
addition to  either  unfractionated  or  low-molecular-weight
heparin. A  loading  dose  (600  mg)  of  clopidogrel  was given
at the  end  of  the procedure.  The  clopidogrel  molecule
was chosen  at  random  between  original  clopidogrel  bisul-
phate, clopidogrel  hydrochloride  or  clopidogrel  besylate.
After treatment  initiation,  the clopidogrel  preparation  was
given for  10  days  at  a dose  of  75  mg/day.  At  days  10  and  20,
the clopidogrel  molecule  was  changed  to  a new  molecule,  so
that after  30  days  all  patients  had  received  all  clopidogrel
preparations for 10 days.  After  this  initial  30-day  period,
a loading  dose  (60 mg)  of  prasugrel  was  given,  followed  by
a maintenance  dose  of 10  mg/day  for  10  days.  After  these
40 days,  the  patient  was  left  for  1 year  on  the  drug  that
provided the  lowest  platelet  reactivity.
Platelet  reactivity assessment
Platelet  reactivity  testing  of  clopidogrel  and  prasugrel  was
performed using  the Multiplate  analyser  (Dynabyte,  Munich,
Germany). This  method  has  been  approved  for  human  use
by  the  United  States  Food  and  Drug  Administration.  The
assay is made  up  of two  distinct  silver  electrode  sensors.
The changes  in the  electrodes’  impedance  after  platelet
adhesion is detected  by  the sensor  and  allows  aggregation
units to  be calculated.  The  variables  evaluated  are:  maxi-
mal aggregation,  velocity  (steepness  of  the  curve) and  area
under the  curve  (AUC,  AU  min),  calculated  from  the mean
values of  the  two  curves.  The  ﬁnal result  is expressed  in
units (U),  with  1  U deﬁned  as  10  AU  min. Platelet  reactivity
was assessed  6  hours  after  the loading  dose  of clopidogrel
and every  10  days  at  the time  of  the  switch  of  the  clopido-
grel preparation.  Efﬁcient  platelet  inhibition  was  deﬁned  as
an adenosine  diphosphate  (ADP)  test  value  < 46  U.  Patients
with values  > 46  U received  a loading  dose  of  another  clopid-
ogrel preparation  on  the  same  day,  with  repeated  platelet
function measurement  after  6 hours.
For the  trial, the  operator  determining  platelet  reactivity
was blinded  to the treatment  arm,  patient  characteristics
and biomarkers.
Statistical analyses
We  performed  a  power  analysis  that  concluded  the  inclu-
sion of 60 patients  at resistance  rates  of  15% for original
clopidogrel and  40%  for the  generic  clopidogrel  preparations
would yield  a statistical  power  of  88% at a  signiﬁcance  level
of alpha  equal  to  0.05  for a  two-tailed  analysis.  The  power
analysis was performed  for  proportions  of  paired  samples.
Continuous  variables  are  presented  as  mean  ±  standard
deviation and  after  conﬁrmation  of a normal  distribution
(QQ plot).  To compare  antiaggregation  units  achieved  with
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Table  1  Patient  characteristics.
Study  cohort  Control  group
(n = 60)  (n  = 50)
Men 50  (83)  12  (24)
Age (years)  68  ± 9  39  ±  10
Body  mass  index  (kg/m2) 27  ± 5  22  ±  4
Diabetes  20  (33)  0
Hypertension 18  (30)  2  (4)
Current smoker 14  (23) 14  (28)
Former smoker 24  (40) 3  (6)
Dyslipidaemia 42 (70) 5  (10)
Family history 22  (37) 13  (26)
Renal failure  4 (7)  0
Heart failure 6  (10)  0
STEMI 0 0
Acute coronary  syndrome 17 (28) 0
Stable angina 28  (47) 0
Silent ischaemia 15  (25) 0
Data are mean ±  standard deviation or number (%). STEMI:
ST-segment elevation myocardial infarction.
the  different  clopidogrel  preparations,  the  paired  t  test  was
employed. Categorical  variables  are  presented  as  numbers
and percentages.  We  considered  a  P  value  <  0.05  as  signiﬁ-
cant. SPSS  software,  version  18 (SPSS Inc.,  Chicago,  IL,  USA)
was used  for  statistical  analyses.
Results
Sixty  patients  (50 men  and  10  women)  with  a mean  age  of
69 ±  10  years  were included.  The  control  group  was  com-
posed of  50  healthy  adults  (22%  men)  who  were not  taking
any  medication  and  had  a  mean  age of  39  ±  10  years.
Patient characteristics  are  shown  in  Table  1.  Brieﬂy,  the
patients had  the usual  risk  factors  expected  in  patients  with
ischaemic  heart  disease.  Baseline  coagulation  variables  and
platelet reactivity  were  normal  for  all  patients  (platelet
count 225  ±  57  g/L,  prothrombin  time  92  ±  13%,  activated
partial thromboplastin  time  33  ±  4  seconds).
After  the  loading  dose,  platelet  reactivity  was  the
same for  all  clopidogrel  preparations,  with  a  mean  value
of 17  ±  15  U for  clopidogrel  bisulphate,  23  ±  16  U for
clopidogrel hydrochloride  and 21  ±  16  U  for clopidogrel  besy-
late (P  =  0.43;  Fig.  2). After  10  days  of  treatment,  there
were no  signiﬁcant  differences  between  the  clopidogrel
preparations, with  a mean  value  of 31  ±  25  U  for clopid-
ogrel bisulphate,  33  ± 28  U for clopidogrel  hydrochloride
and 28  ±  23 U for clopidogrel  besylate  (P = 0.69;  Table  2;
Fig. 3).  There  were no  statistical  differences  between
the groups:  clopidogrel  bisulphate  vs.  clopidogrel  besylate
(P =  0.58);  clopidogrel  bisulphate  vs. clopidogrel  hydrochlo-
ride (P  =  0.34);  and  clopidogrel  hydrochloride  vs.  clopidogrel
besylate (P = 0.14)  (Fig.  3). For  all  clopidogrel  preparations,
the higher  platelet  reactivity  inhibition  was  obtained  after
the loading  dose,  as  shown  in  Table  2.  Eleven  (18%)  patients
showed values  >  46  U  for clopidogrel  bisulphate,  13  patients
Figure 2.  Distribution of platelet reactivity after  loading dose.
Figure 3.  Distribution of platelet reactivity after 10 days of  treat-
ment.
(22%)  for  clopidogrel  hydrochloride  and  13  patients  (22%)  for
clopidogrel besylate  (Table  2).
Prasugrel  was  signiﬁcantly  more  efﬁcient  than  any  prepa-
ration of clopidogrel,  with  a mean  value  of  10  ± 11  U
(P < 0.001);  only  one  patient  (2%)  exhibited  a value  >  46  U.
Discussion
Stent  thrombosis  remains  a  partially  unsolved  problem,
associated with  a high  rate  of  morbidity  and  mortality
after PCI.  A  signiﬁcantly  higher  rate  of  stent thrombosis  in
patients with  higher  on-treatment  platelet  reactivity  has
been  reported,  with  an incidence  of up to 3%  [8].  Also,
using the  P2Y12  point-of-care  assay,  high  platelet  reactiv-
ity (P2Y12  reactivity  units  > 230)  was  associated  with  higher
rates of  death,  myocardial  infarction  or  stent  thrombo-
sis. Thus,  as  clopidogrel  has  become  generic,  with  several
commercial preparations  now  available,  it  is of critical
importance to  demonstrate  that  similar  inhibition  of  platelet
reactivity can  be achieved  with  these  preparations.
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Table  2  Mean  antiaggregation  values  for  the  treated  population  and  controls  (adenosine  diphosphate  test).
n Mean U ± standard  deviation  % of  patients  with
ADP test  value  <  46  U
No  treatment  Loading  dose  Maintenance  dose
Clopidogrel  bisulphate
(Plavix®)
60  17  ±  15  31  ±  25  82
Clopidogrel besylate
(Clopidogrel
Sandoz®)
60 21 ±  16  28 ±  23  78
Clopidogrel
hydrochloride
(Clopidogrel-Mepha®)
60 23  ±  16  33  ±  28  78
Prasugrel (Eﬁent®)  60  6 ±  16  10  ±  11  98
Control group  (no
treatment)
50  61  ±  17
ADP:  adenosine diphosphate; U: antiaggregation units.
In  this  prospective  trial,  we  showed  that  all  preparations
of clopidogrel  tested  provide  similar  inhibition  of  platelet
reactivity and  that  generic  preparations  can be used  safely
after PCI.  We  found  36  patients  (21.9%)  taking  any  clopid-
ogrel who  had  an  ADP test  value  >  46  U; they  have  to  be
considered as clopidogrel  resistant.  This  is  in  line with  pre-
vious reports  showing  clopidogrel  resistance  in  23  to  40% of
patients [9].  Our  results  show  a wide  response  variability;
thus a  clear  cut-off  value  to  deﬁne  true clopidogrel  resis-
tance has  still  to be determined,  as  in  other  reported  trials
[10]. Furthermore,  platelet  reactivity  is not  the only vari-
able involved  in stent  thrombosis-implantation  technique,
angiographic result  and  clinical  status  (such  as  acute  coro-
nary syndrome  or  comorbidities  such as  diabetes)  also affect
the rate  of  stent  thrombosis  and  morbidity  [11].
It  has  also  been  recently  shown  that  the incidence  of
major adverse  clinical  events,  including  stent  thrombosis,
is higher  when  platelet  reactivity  is still present  at a high
value (>  46  U)  when  the Multiplate  analyser  is  used  [4,8].
Our  data  conﬁrm  the  results  of  two  previous  trials
comparing original  clopidogrel  with  generic  clopidogrel
preparations in  healthy  subjects  [12,13].  These  trials
showed similar  safety  proﬁles  and  met  the  criteria  for  phar-
macokinetic bioequivalence.  Only  healthy  volunteers  were
included in  these  studies,  which  is a limitation  because
patients with  atherosclerotic  disease  have  a  higher  degree  of
variability in  their  response  to  clopidogrel  due to  comorbidi-
ties and  multiple  comedications.  Our trial,  by comparison,
was conducted  in  a real-life  setting,  with  patients  who had
a clinical  indication  for  antiplatelet  therapy.
In  addition,  our  data  conﬁrm  the  value  of prasugrel
as a  potent  antiplatelet  agent.  Prasugrel,  like  clopidogrel,
requires conversion  to  an  active  metabolite  before  bind-
ing to  the  platelet  P2Y12  receptor  to  confer  antiplatelet
activity. Prasugrel  inhibits  ADP-induced  platelet  aggregation
more rapidly,  more  consistently  and  to  a  greater  extent
than standard  and  higher  doses  of clopidogrel  in healthy
volunteers and  in  patients  with  coronary  artery  disease
undergoing PCI  [14—16].  When  antiaggregation  is of criti-
cal importance  (patients  with  multiple  stenting,  multivessel
disease  or  left  main  PCI, diabetic  patients,  etc.),  clopidogrel
resistance can  be  avoided  with  prescription  of prasugrel,
along with  very efﬁcient  inhibition  of  platelet  reactivity.
Study  limitations
The  main  limitation  of this  trial  was the  small  number
of patients.  However,  it seems  obvious  that  a signiﬁcant
difference between  the  original  and  generic  clopidogrel
preparations would  require  a considerable  number  of
patients to  show  very  little  difference.  Moreover,  any  bene-
ﬁt favouring  one  of the  preparations  would  not  necessarily
be correlated  with  better  clinical  outcome.  As  the platelet
reactivity test  has  limitations,  its  routine  use in  clinics  also
has limitations  and  results  should  be  interpreted  in the  set-
ting of the  clinical  situation.  Finally,  there  are  no  large-scale
trials that  show  clinical  outcome  improvement  after  adap-
tation of  antiplatelet  therapy  using  the  platelet  reactivity
test [8].
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